RECRUITINGINTERVENTIONAL
Maintenance Venetoclax in AML Fit Patients
Maintenance Venetoclax Based Therapy Post Complete Remission in AML Fit Patients
About This Trial
this study will explore the efficacy of maintenance SC cytarabine + venetoclax therapy as regard disease free survival (DFS) in AML fit patients who achieved CR after highly aggressive chemotherapy as bridge for BMT or if BMT will be delayed or canceled due to any other reason.
Who May Be Eligible (Plain English)
Who May Qualify:
- Age : 18 - 60 years . Patients who are not eligible for immediate bone marrow transplantation. Newly diagnosed AML patients who attained CR after 1st line. Refractory / recurrant AML patients who attained CR after 2nd line .
Who Should NOT Join This Trial:
- Patients not on CR . Age : younger than 18 or older than 60 . Patients not eligible for bone marrow transplation
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age : 18 - 60 years . Patients who are not eligible for immediate bone marrow transplantation. Newly diagnosed AML patients who attained CR after 1st line. Refractory / recurrant AML patients who attained CR after 2nd line .
Exclusion Criteria:
* Patients not on CR . Age : younger than 18 or older than 60 . Patients not eligible for bone marrow transplation
Treatments Being Tested
DRUG
SC cytarabine +Venetoclax
SC Cytarabine (20 mg) administrated on days 1-7 ,,Venetoclax (100 mg ) administrated on days 1-7,,Voriconazole 200 mg 1x2 administrated on days , Best supportive care as needed . Up to 12 cycles or until patients undergo bone marrow transplantation
Locations (2)
Sohag university hospital
Sohag, Egypt
Sohag university
Sohag, Egypt